Y. Shparyk

发表

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Jianying Zhou, Erdem Goker, Jun Zhao, 2019, The Lancet.

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.

A. Oza, I. Bondarenko, N. Colombo, 2022, The Lancet. Oncology.

Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.

Joon-Oh Park, M. Buyse, Y. Bang, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.

M. Atkins, E. Plimack, B. Melichar, 2021, European urology oncology.

An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer.

C. Waller, I. Vynnychenko, I. Bondarenko, 2015, Clinical lung cancer.

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

T. Ciuleanu, N. Thatcher, M. O'Brien, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O-157 Survival benefit of oral topotecan plus supportive care versus supportive care alone in relapsed, resistant SCLC

T. Ciuleanu, M. O'Brien, G. Ross, 2005 .

Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)

R. Finn, T. Pintér, J. Crown, 2012 .

Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study

I. Bondarenko, T. Eisen, Y. Shparyk, 2013, Investigational New Drugs.

Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial

H. Wildiers, B. Arun, M. Friedlander, 2021, Therapeutic advances in medical oncology.

A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis

M. Gore, G. Hedlund, R. Hawkins, 2016, Clinical Cancer Research.

Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 javelin ovarian 100 trial

B. Monk, A. Oza, J. Ledermann, 2020 .

Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)

R. Finn, Marcus Schmidt, I. Bondarenko, 2014 .

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Young Hak Kim, N. Reinmuth, A. Chiang, 2019, The Lancet.

2509 Overall survival analysis from a randomised phase III trial of axitini vs sorafenib as first-line therapy in patients with metastatic renal cell carcinoma

N. Vogelzang, Thomas E. Hutson, O. Lipatov, 2015 .

O-163 Prevention of thromboembolic complications with the low-molecular-weight heparin certoparin in non-small-cell lung carcinoma (TOPIC-2)

U. Gatzemeier, T. Ciuleanu, P. Zatloukal, 2005 .

Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18).

R. Finn, Marcus Schmidt, I. Bondarenko, 2017 .

Axitinib Versus Sorafenib in First‐Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial

N. Vogelzang, Thomas E. Hutson, O. Lipatov, 2017, Clinical genitourinary cancer.

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.

D. Miles, D. Cameron, J. Canon, 2017, European journal of cancer.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

M. Lux, R. Greil, A. Schneeweiss, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri

G. D'Haens, C. Stroh, J. Zaluski, 2008 .

Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2 positive advanced or metastatic gastric (A/MGC), esophageal (EAC), or gastroesophageal (GEJ) adenocarcinoma: The LOGiC trial.

Joon-Oh Park, M. Buyse, Y. Bang, 2013 .

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.

H. Wildiers, Yeon-Hee Park, M. Friedlander, 2020, The Lancet. Oncology.

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

K. Wilner, R. Finn, Marcus Schmidt, 2020, Breast Cancer Research and Treatment.

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

W. Gradishar, J. Garber, A. Jager, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients.

R. Kaiser, I. Bondarenko, T. Eisen, 2013 .

BRCA1 4153delA mutation (”Baltic/Black Sea”) in breast cancer patients in Ukraine

Y. Shparyk, B. Bilynsky, N. Kitsera, 2014 .

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.

Joon-Oh Park, M. Buyse, Y. Bang, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer

H. Wildiers, Yeon-Hee Park, M. Friedlander, 2019, Annals of Oncology.

A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.

I. Bondarenko, Y. Shparyk, V. Moiseyenko, 2016, The oncologist.

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

P. Neven, K. Gelmon, H. Rugo, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Xin Huang, Johannes Ettl, Marcus Schmidt, 2015, The Lancet. Oncology.

Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4.

A. Oza, I. Bondarenko, N. Colombo, 2021 .

Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.

B. Monk, A. Oza, J. Ledermann, 2021, The Lancet. Oncology.

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)

Y. Hotko, K. Syrigos, M. Gumus, 2021, BioDrugs.

Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.

F. Franke, I. Bondarenko, V. Ostwal, 2018, The lancet. Gastroenterology & hepatology.

Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3

S. Loi, H. Rugo, R. Finn, 2022, Breast.

Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia

I. Láng, M. Bronchud, L. Mattano, 2019, Annals of Hematology.

Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial

Bing-he Xu, I. Bondarenko, Wei Li, 2021, BioDrugs.

Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor–Positive Locally Advanced or Metastatic Breast Cancer

G. Acton, N. Ibrahim, J. Murray, 2011, Clinical Cancer Research.

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.

V. Semiglazov, X. Pivot, S. Chatterjee, 2018, European journal of cancer.

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

M. Ellis, J. Robertson, A. Manikhas, 2016, The Lancet.

FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer

M. Ellis, J. Robertson, A. Manikhas, 2016 .

Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.

A. Carrato, J. Christensen, E. Van Cutsem, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region

T. Ciuleanu, C. Szczylik, M. Mego, 2012, Expert opinion on pharmacotherapy.

Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

V. Semiglazov, X. Pivot, S. Chatterjee, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy

I. Bondarenko, Y. Shparyk, V. Moiseyenko, 2015, Medical Oncology.

Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer

J. Ahn, G. Lyman, G. Curigliano, 2023, JAMA network open.

A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results

I. Bondarenko, T. Eisen, M. Mazurkiewicz, 2015, British Journal of Cancer.

Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel, in patients with metastatic breast cancer (MBC) as first-line treatment.

Sudeep Gupta, Y. Im, A. Makhson, 2013 .

Palbociclib (PAL) + letrozole (L) as first-line (1L) therapy (tx) in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Efficacy and safety across patient (pt) subgroups.

K. Gelmon, H. Rugo, H. Mukai, 2017 .

A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer

J. Ajani, M. Alsina, J. Feliu, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

1866 First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) +/- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC)

D. Miles, D. Cameron, J. Canon, 2015 .

Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.

F. Moiseenko, A. Falcone, N. Amellal, 2022, The lancet. Gastroenterology & hepatology.

A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis

M. Gore, G. Hedlund, R. Hawkins, 2016, Clinical Cancer Research.

A randomized phase II/III study of naptumomab estafenatox plus IFN-α versus IFN-α in advanced renal cell carcinoma.

M. Gore, G. Hedlund, R. Hawkins, 2013 .

Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.

Joon-Oh Park, M. Buyse, Y. Bang, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.

T. Crocenzi, Tae-You Kim, Y. Hotko, 2024, Annals of oncology : official journal of the European Society for Medical Oncology.

Effects of nintedanib (BIBF 1120) on QTc interval in previously untreated patients with renal cell cancer (RCC): Results from an open-label, phase II study.

I. Bondarenko, T. Eisen, Y. Shparyk, 2012 .